帕博利珠单抗治疗晚期胃及胃食管结合部腺癌。
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
机构信息
Section of Hematology/Oncology, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.
The University of Chicago Medical Center & Biological Sciences, 900 East 57th Street, KCBD Building, Office 7128, Chicago, IL 60637, USA.
出版信息
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
Abstract
Pembrolizumab is a monoclonal antibody directed against PD-1 that is US FDA approved for treatment of advanced PD-L1 positive gastric and gastroesophageal junction adenocarcinoma in patients who have progressed on at least two prior lines of chemotherapy. This article summarizes the clinical evidence regarding safety, tolerability and efficacy of pembrolizumab in this setting. In addition, this article describes the investigational use of pembrolizumab as first- and second-line therapy and in combination with other treatments. Finally, this review compares other checkpoint inhibitors to pembrolizumab for the treatment of this disease, and explores predictive biomarkers of response to PD-1 blockade.
摘要
帕博利珠单抗是一种针对 PD-1 的单克隆抗体，已获美国食品药品监督管理局批准，用于治疗至少接受过两种化疗方案治疗后进展的 PD-L1 阳性胃及胃食管结合部腺癌。本文总结了帕博利珠单抗在这一适应证下的安全性、耐受性和疗效的临床证据。此外，本文还介绍了帕博利珠单抗作为一线和二线治疗以及与其他治疗方法联合应用的研究情况。最后，本文对其他检查点抑制剂与帕博利珠单抗治疗该疾病进行了比较，并探讨了 PD-1 阻断治疗反应的预测生物标志物。
相似文献
1
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.帕博利珠单抗治疗晚期胃及胃食管结合部腺癌。
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
2
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.FDA 批准概要：帕博利珠单抗用于表达 PD-L1 的复发性局部晚期或转移性胃或胃食管连接部腺癌。
Oncologist. 2019 Jan;24(1):103-109. doi: 10.1634/theoncologist.2018-0221. Epub 2018 Aug 17.
3
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.免疫检查点抑制在胃食管交界处癌中的应用
Oncol Res Treat. 2018;41(5):272-280. doi: 10.1159/000489099. Epub 2018 Apr 27.
4
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].新药批准：帕博利珠单抗联合化疗作为晚期/转移性食管癌或HER阴性胃食管腺癌的一线治疗，其PD-L1表达且CPS≥10
Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.
5
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
6
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比紫杉醇用于治疗晚期或胃食管结合部腺癌（KEYNOTE-061）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.
7
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.KEYNOTE-859：帕博利珠单抗联合化疗治疗胃/胃食管结合部腺癌的 III 期研究。
Future Oncol. 2021 Aug;17(22):2847-2855. doi: 10.2217/fon-2021-0176. Epub 2021 May 12.
8
Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma.帕博利珠单抗与紫杉醇治疗胃食管腺癌的对比
Lancet. 2018 Jul 14;392(10142):97-98. doi: 10.1016/S0140-6736(18)31277-7. Epub 2018 Jun 4.
9
Current status of ramucirumab in gastroesophageal adenocarcinoma.雷莫芦单抗在胃食管腺癌中的应用现状。
Future Oncol. 2017 Aug;13(18):1585-1592. doi: 10.2217/fon-2016-0556. Epub 2017 Apr 24.
10
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗用于一线治疗晚期食管鳞状细胞癌和胃/胃食管交界腺癌的安全性和有效性。
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.
引用本文的文献
1
Galectin-9 and Tim-3 in gastric cancer: a checkpoint axis driving T cell exhaustion and Treg-mediated immunosuppression independently of anti-PD-1 blockade.胃癌中的半乳糖凝集素-9和Tim-3：一个驱动T细胞耗竭和调节性T细胞介导的免疫抑制的检查点轴，独立于抗程序性死亡蛋白1阻断作用
Front Immunol. 2025 Jul 1;16:1600792. doi: 10.3389/fimmu.2025.1600792. eCollection 2025.
2
The PD-1/PD-L1 pathway and Epstein-Barr virus.PD-1/PD-L1通路与爱泼斯坦-巴尔病毒。
Eur J Med Res. 2025 Jun 18;30(1):486. doi: 10.1186/s40001-025-02694-1.
3
Assessment of Quality of Life and Difficulties in Recording Data from Health-Related Quality of Life Questionnaires in Patients with Cancer Undergoing Immunotherapy Treatment.接受免疫治疗的癌症患者生活质量评估及健康相关生活质量问卷数据记录困难分析
Healthcare (Basel). 2025 Apr 26;13(9):1002. doi: 10.3390/healthcare13091002.
4
Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data.肥胖和炎症对胃癌免疫治疗疗效的矛盾影响：来自真实世界数据的新见解
Gastric Cancer. 2025 May 12. doi: 10.1007/s10120-025-01622-w.
5
The expression and prognostic value of in esophageal squamous cell carcinoma.[具体内容]在食管鳞状细胞癌中的表达及预后价值。 （这里原文“of”后面缺少具体内容，翻译根据语境补齐了“[具体内容]”）
Transl Cancer Res. 2024 Nov 30;13(11):6219-6234. doi: 10.21037/tcr-24-233. Epub 2024 Nov 1.
6
Association between infection, mismatch repair, HER2 and tumor-infiltrating lymphocytes in gastric cancer.胃癌中感染、错配修复、人表皮生长因子受体2（HER2）与肿瘤浸润淋巴细胞之间的关联
World J Gastrointest Oncol. 2024 Jun 15;16(6):2487-2503. doi: 10.4251/wjgo.v16.i6.2487.
7
Unveiling Therapeutic Targets for Esophageal Cancer: A Comprehensive Review.揭示食管癌的治疗靶点：全面综述。
Curr Oncol. 2023 Oct 30;30(11):9542-9568. doi: 10.3390/curroncol30110691.
8
Combined Use of Immune Checkpoint Inhibitors and Phytochemicals as a Novel Therapeutic Strategy against Cancer.免疫检查点抑制剂与植物化学物质联合使用作为一种新型抗癌治疗策略。
J Cancer. 2023 Jul 24;14(12):2315-2328. doi: 10.7150/jca.85966. eCollection 2023.
9
Visceral adipose tissue secretome from early and late-stage oesophageal cancer patients differentially affects effector and regulatory T cells.早期和晚期食管癌患者内脏脂肪组织分泌组对效应和调节性 T 细胞有不同影响。
J Cancer Res Clin Oncol. 2023 Aug;149(9):6583-6599. doi: 10.1007/s00432-023-04620-6. Epub 2023 Feb 15.
10
Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment.癌症治疗中的免疫疗法：帕博利珠单抗治疗非小细胞肺癌临床疗效的文献综述
Adv Pharm Bull. 2023 Jan;13(1):88-95. doi: 10.34172/apb.2023.007. Epub 2021 Oct 10.
本文引用的文献
1
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞罗西单抗联合表柔比星、顺铂和卡培他滨作为晚期MET阳性胃癌或胃食管交界癌的一线治疗（RILOMET-1）：一项随机、双盲、安慰剂对照的3期试验。
Lancet Oncol. 2017 Nov;18(11):1467-1482. doi: 10.1016/S1470-2045(17)30566-1. Epub 2017 Sep 25.
2
Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology.免疫时代胃癌肿瘤浸润淋巴细胞的临床意义
World J Gastrointest Oncol. 2017 Jul 15;9(7):293-299. doi: 10.4251/wjgo.v9.i7.293.
3
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.PD-1和PD-L1作为胃癌新出现的治疗靶点：当前证据
Gastrointest Cancer. 2017;7:1-11. doi: 10.2147/GICTT.S113525. Epub 2017 May 5.
4
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
5
Evaluation of dosing strategy for pembrolizumab for oncology indications.评估派姆单抗在肿瘤适应证中的给药策略。
J Immunother Cancer. 2017 May 16;5:43. doi: 10.1186/s40425-017-0242-5. eCollection 2017.
6
Update on Gastroesophageal Adenocarcinoma Targeted Therapies.胃食管腺癌靶向治疗的最新进展
Hematol Oncol Clin North Am. 2017 Jun;31(3):511-527. doi: 10.1016/j.hoc.2017.01.009.
7
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.调节PD-L1和PD-L2表达的干扰素受体信号通路
Cell Rep. 2017 May 9;19(6):1189-1201. doi: 10.1016/j.celrep.2017.04.031.
8
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.曲妥珠单抗-美坦新偶联物对比紫杉烷类药物用于既往治疗的人表皮生长因子受体 2（HER2）阳性局部晚期或转移性胃或胃食管结合部腺癌（GATSBY）：一项国际、随机、开放标签、适应性、2/3 期研究。
Lancet Oncol. 2017 May;18(5):640-653. doi: 10.1016/S1470-2045(17)30111-0. Epub 2017 Mar 23.
9
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.一项非小细胞肺癌中 PD-L1 表达的前瞻性、多机构、基于病理学家的 4 种免疫组化检测评估。
JAMA Oncol. 2017 Aug 1;3(8):1051-1058. doi: 10.1001/jamaoncol.2017.0013.
10
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.错配修复缺陷、微卫星不稳定与生存：英国医学研究理事会辅助胃输注化疗（MAGIC）试验的探索性分析
JAMA Oncol. 2017 Sep 1;3(9):1197-1203. doi: 10.1001/jamaoncol.2016.6762.
Zotero 插件